Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.39 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.39 |
| ▸ | GLRB | P48167 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29709817 | 1.00 | CREBBP (0.41) | CREBBPGPR119GLRA3GLRA1GLRB | |
| SCHEMBL24794177 | 0.86 | ALDH1A1 (0.50) | GPR119 | |
| SCHEMBL24793633 | 0.85 | CREBBP (0.41) | CREBBP | |
| SCHEMBL29709647 | 0.85 | CREBBP (0.41) | CREBBP | |
| SCHEMBL24793649 | 0.84 | JAK1 (0.42) | CREBBPGPR119 | |
| SCHEMBL24792918 | 0.83 | EPHX2 (0.41) | GPR119LIPE | |
| SCHEMBL24792917 | 0.83 | NR1H2 (0.47) | CREBBP | |
| SCHEMBL24794739 | 0.82 | ENPP2 (0.45) | ATXN2 | |
| SCHEMBL29709766 | 0.82 | ENPP2 (0.45) | ATXN2 | |
| SCHEMBL24793630 | 0.81 | ATXN2 (0.48) | ATXN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402901-A1 | SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS | BIAL R&D INVEST S A (PT) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402901-A1 | SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS | ASAH2, ASAH1, GBA1 | CREBBP 1406/4885GPR119 1919/4885GLRA3 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.